Cytokine storm release syndrome and the prospects for immunotherapy with COVID-19, part 3: The role of GM-CSF

Link to article at PubMed

Cleve Clin J Med. 2020 Aug 12. doi: 10.3949/ccjm.87a.ccc057. Online ahead of print.


Granulocyte-macrophage colony-stimulating factor (GM-CSF) has been used experimentally in patients with acute respiratory distress syndrome. Recombinant GM-CSF administered by direct inhalation is currently being studied in a cohort of patients with advanced COVID-19.

PMID:32753517 | DOI:10.3949/ccjm.87a.ccc057

Leave a Reply

Your email address will not be published.